Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QuidelOrtho Corporation (Nasdaq: QDEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an issuer in the in vitro diagnostics and medical device manufacturing space, QuidelOrtho uses these filings to report on its financial condition, capital structure, material agreements and other significant events.
Investors can review current reports on Form 8‑K, where QuidelOrtho furnishes press releases announcing quarterly financial results, earnings conference calls and stockholder letters discussing recent performance and strategic priorities. For example, 8‑K filings in November 2025 reference third‑quarter results and a stockholder communication, while an August 21, 2025 8‑K details a Credit Agreement that established senior secured term loan A and term loan B facilities and a revolving credit facility with a syndicate of lenders.
Alongside 8‑Ks, users can also access annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide more comprehensive information on QuidelOrtho’s business, including its diagnostic segments in clinical chemistry, immunoassay, immunohematology and molecular testing. These reports typically include discussions of risk factors, research and development spending, and other elements that shape the company’s long‑term outlook.
For those interested in governance and ownership, proxy statements and beneficial ownership reports (such as Forms 3, 4 and 5) can be used to analyze executive and director holdings and transactions, although specific examples are not detailed here. Together, these documents form a record of how QuidelOrtho communicates with regulators and investors about its operations and capital decisions.
Stock Titan enhances this information by pairing real‑time EDGAR updates with AI‑powered summaries that explain the key points of long filings in plain language. Users can quickly see what each new 10‑K, 10‑Q, 8‑K or Form 4 means for QuidelOrtho without reading every page, while still having direct access to the full text for deeper review.
QuidelOrtho (QDEL) reported an insider equity award event. Chief Legal Officer Michelle A. Hodges had 390 restricted stock units vest on October 15, 2025, converting into 390 common shares at $0. To cover tax withholding, 199 shares were withheld at $27.31. Following these transactions, she directly beneficially owned 29,403 common shares.
Ronald Lee Bowman, Chief Human Resources Officer of QuidelOrtho Corporation (QDEL), reported issuance and vesting activity on 09/15/2025. 2,565 restricted stock units (RSUs) vested and were released into common stock. To satisfy tax withholding obligations, the issuer withheld 918 shares (disposed at an effective price of $28.92 per share), leaving 1,647 shares of common stock directly owned by Bowman after the transaction. The filing also shows 5,132 RSUs remain outstanding and will vest in equal installments on 09/15/2026 and 09/15/2027. The Form 4 was signed by an attorney-in-fact on behalf of Bowman on 09/17/2025.
QuidelOrtho Corporation disclosed that it entered into a Credit Agreement dated Aug 21, 2025 under which the company is the borrower and Bank of America, N.A. serves as administrative agent and swing line lender, with other lenders and letter-of-credit issuers participating. The filing incorporates Item 1.01 information by reference and attaches the Credit Agreement as Exhibit 10.1. A press release dated Aug 21, 2025 and embedded Inline XBRL cover page data are also noted. The filing is signed by the company’s CFO, indicating the agreement is a disclosed material event; specific financial terms, committed facility size, covenants, maturity, and pricing are not provided in the text available.